G Protein Signaling-biased Mu Opioid Receptor Agonists That Produce Sustained G Protein Activation Are Noncompetitive Agonists

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2021 Nov 25

PMID 34819362

Citations 11

Authors

Edward L Stahl

Cullen L Schmid

Agnes Acevedo-Canabal

Cai Read

Travis W Grim

Nicole M Kennedy

Thomas D Bannister

Laura M Bohn

Affiliations

Soon will be listed here.

Abstract

The ability of a ligand to preferentially promote engagement of one signaling pathway over another downstream of GPCR activation has been referred to as signaling bias, functional selectivity, and biased agonism. The presentation of ligand bias reflects selectivity between active states of the receptor, which may result in the display of preferential engagement with one signaling pathway over another. In this study, we provide evidence that the G protein-biased mu opioid receptor (MOR) agonists SR-17018 and SR-14968 stabilize the MOR in a wash-resistant yet antagonist-reversible G protein-signaling state. Furthermore, we demonstrate that these structurally related biased agonists are noncompetitive for radiolabeled MOR antagonist binding, and while they stimulate G protein signaling in mouse brains, partial agonists of this class do not compete with full agonist activation. Importantly, opioid antagonists can readily reverse their effects in vivo. Given that chronic treatment with SR-17018 does not lead to tolerance in several mouse pain models, this feature may be desirable for the development of long-lasting opioid analgesics that remain sensitive to antagonist reversal of respiratory suppression.

Citing Articles

Biased Opioid Receptor Agonists: Balancing Analgesic Efficacy and Side-Effect Profiles.

Ju J, Li Z, Liu J, Peng X, Gao F Int J Mol Sci. 2025; 26(5).

PMID: 40076488 PMC: 11899445. DOI: 10.3390/ijms26051862.

Exploring the constitutive activation mechanism of the class A orphan GPR20.

Zhang M, Ao J, Liu N, Chen T, Lu S Acta Pharmacol Sin. 2024; 46(2):500-511.

PMID: 39256608 PMC: 11747167. DOI: 10.1038/s41401-024-01385-7.

GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents.

Klein A, Austin E, Cunningham M, Dvorak D, Gatti S, Hulls S Neuropsychopharmacology. 2024; 49(6):905-914.

PMID: 38177696 PMC: 11039472. DOI: 10.1038/s41386-023-01783-1.

Differential interaction patterns of opioid analgesics with µ opioid receptors correlate with ligand-specific voltage sensitivity.

Kirchhofer S, Lim V, Ernst S, Karsai N, Ruland J, Canals M Elife. 2023; 12.

PMID: 37983079 PMC: 10849675. DOI: 10.7554/eLife.91291.

Assessment of the potential of novel and classical opioids to induce respiratory depression in mice.

Hill R, Sanchez J, Lemel L, Antonijevic M, Hosking Y, Mistry S Br J Pharmacol. 2023; 180(24):3160-3174.

PMID: 37489013 PMC: 10952895. DOI: 10.1111/bph.16199.

References

Sharma S, Klee W, Nirenberg M . Opiate-dependent modulation of adenylate cyclase. Proc Natl Acad Sci U S A. 1977; 74(8):3365-9. PMC: 431562. DOI: 10.1073/pnas.74.8.3365. View

Pasternak G . Mu Opioid Pharmacology: 40 Years to the Promised Land. Adv Pharmacol. 2018; 82:261-291. DOI: 10.1016/bs.apha.2017.09.006. View

Selley D, Sim L, Xiao R, Liu Q, Childers S . mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol. 1997; 51(1):87-96. DOI: 10.1124/mol.51.1.87. View

Gregory K, Sexton P, Tobin A, Christopoulos A . Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor. J Biol Chem. 2012; 287(44):37066-77. PMC: 3481307. DOI: 10.1074/jbc.M112.408534. View

Whalen E, Rajagopal S, Lefkowitz R . Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med. 2010; 17(3):126-39. PMC: 3628754. DOI: 10.1016/j.molmed.2010.11.004. View

Podlewska S, Bugno R, Kudla L, Bojarski A, Przewlocki R . Molecular Modeling of µ Opioid Receptor Ligands with Various Functional Properties: PZM21, SR-17018, Morphine, and Fentanyl-Simulated Interaction Patterns Confronted with Experimental Data. Molecules. 2020; 25(20). PMC: 7594085. DOI: 10.3390/molecules25204636. View

Ott S, Costa T, Herz A . Sodium modulates opioid receptors through a membrane component different from G-proteins. Demonstration by target size analysis. J Biol Chem. 1988; 263(21):10524-33. View

Raehal K, Bohn L . The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics. Neuropharmacology. 2010; 60(1):58-65. PMC: 2981657. DOI: 10.1016/j.neuropharm.2010.08.003. View

Pert C, Pasternak G, Snyder S . Opiate agonists and antagonists discriminated by receptor binding in brain. Science. 1973; 182(4119):1359-61. DOI: 10.1126/science.182.4119.1359. View

10.

Ehlert F . Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol. 1988; 33(2):187-94. View

11.

Zaki P, Keith Jr D, Brine G, Carroll F, Evans C . Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?. J Pharmacol Exp Ther. 2000; 292(3):1127-34. View

12.

Jauzac P, Frances B, Puget A, Moisand C, Meunier J . Differential regulation of two molecular forms of a mu-opioid receptor type by sodium ions, manganese ions and by guanyl-5'-yl imidodiphosphate. J Recept Res. 1986; 6(1):1-25. DOI: 10.3109/10799898609073921. View

13.

Connor M, Bagley E, Chieng B, Christie M . β-Arrestin-2 knockout prevents development of cellular μ-opioid receptor tolerance but does not affect opioid-withdrawal-related adaptations in single PAG neurons. Br J Pharmacol. 2014; 172(2):492-500. PMC: 4292963. DOI: 10.1111/bph.12673. View

14.

Schmid C, Kennedy N, Ross N, Lovell K, Yue Z, Morgenweck J . Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell. 2017; 171(5):1165-1175.e13. PMC: 5731250. DOI: 10.1016/j.cell.2017.10.035. View

15.

Grim T, Schmid C, Stahl E, Pantouli F, Ho J, Acevedo-Canabal A . A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal. Neuropsychopharmacology. 2019; 45(2):416-425. PMC: 6901606. DOI: 10.1038/s41386-019-0491-8. View

16.

Pasternak G, Snyder S . Identification of novel high affinity opiate receptor binding in rat brain. Nature. 1975; 253(5492):563-5. DOI: 10.1038/253563a0. View

17.

Groer C, Tidgewell K, Moyer R, Harding W, Rothman R, Prisinzano T . An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization. Mol Pharmacol. 2006; 71(2):549-57. PMC: 3926195. DOI: 10.1124/mol.106.028258. View

18.

Raehal K, Schmid C, Groer C, Bohn L . Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev. 2011; 63(4):1001-19. PMC: 3186080. DOI: 10.1124/pr.111.004598. View

19.

Williams J, Ingram S, Henderson G, Chavkin C, Von Zastrow M, Schulz S . Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013; 65(1):223-54. PMC: 3565916. DOI: 10.1124/pr.112.005942. View

20.

Wang D, Raehal K, Lin E, Lowery J, Kieffer B, Bilsky E . Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther. 2003; 308(2):512-20. DOI: 10.1124/jpet.103.054049. View